TABLE 4.
Changes in intra-hepatic triglyceride content
| IHTG content (%) | FHBL no-dosing (n = 6) | HeFH placebo (n = 11) | Mipomersen (n = 10) |
|---|---|---|---|
| Baseline | |||
| Mean ± SD | 21.9 ± 6.5 | 1.2 ± 1.0 | 1.2 ± 1.0 |
| Range | 13.2 – 30.1 | 0.2 – 3.2 | 0.3 – 3.8 |
| Week 4 | |||
| Mean ± SD | 21.7 ± 5.9 | 1.2 ± 1.1 | 1.0 ± 0.5 |
| Range | 11.9 – 27.6 | 0.2 – 3.3 | 0.4 – 1.9 |
| Week 15 | |||
| Mean ± SD | 22.6 ± 6.8 | 1.1 ± 0.8 | 2.1 ± 1.5 |
| Range | 12.7 – 31.0 | 0.2 – 2.5 | 0.8 – 5.7 |
| Change from baseline to week 15 | |||
| Mean ± SD | 0.7 ± 2.1 | −0.1 ± 0.9 | 0.8 ± 1.7a |
| Range | −2.0 – 4.3 | −1.5 – 1.3 | −1.7 – 5.1 |
FHBL, familial hypobetalipoproteinemia; HeFH, heterozygous familial hypercholesterolemia; IHTG, intra-hepatic triglyceride content.
a
P = 0.0513 compared with placebo using the Exact Wilcoxon Rank sum test.